| Primary |
| Candida Pneumonia |
20.0% |
| Candidiasis |
20.0% |
| Febrile Neutropenia |
20.0% |
| Fungal Infection |
20.0% |
| Pulmonary Aspergillosis |
20.0% |
|
| Blood Alkaline Phosphatase Increased |
33.3% |
| Aspartate Aminotransferase Increased |
16.7% |
| Haematocrit Decreased |
16.7% |
| Hepatotoxicity |
16.7% |
| Swollen Tongue |
16.7% |
|
| Secondary |
| Product Used For Unknown Indication |
31.5% |
| Abdominal Infection |
8.8% |
| Drug Use For Unknown Indication |
7.4% |
| Pain |
6.8% |
| Antifungal Prophylaxis |
6.6% |
| Retroperitoneal Abscess |
5.8% |
| Bronchopulmonary Aspergillosis |
4.0% |
| Acute Myeloid Leukaemia |
3.4% |
| Evidence Based Treatment |
3.0% |
| Pyrexia |
2.6% |
| Renal Transplant |
2.6% |
| Anxiety |
2.4% |
| Infection |
2.4% |
| Candidiasis |
2.2% |
| Oral Candidiasis |
2.0% |
| Aspergillosis |
1.8% |
| Ill-defined Disorder |
1.8% |
| Immunosuppression |
1.8% |
| Prophylaxis |
1.8% |
| Aspergillus Infection |
1.6% |
|
| Venoocclusive Liver Disease |
22.7% |
| Death |
7.2% |
| Stevens-johnson Syndrome |
7.2% |
| Venoocclusive Disease |
7.2% |
| Respiratory Failure |
6.2% |
| Septic Shock |
6.2% |
| Drug Ineffective |
4.1% |
| Drug Resistance |
4.1% |
| Renal Failure Acute |
4.1% |
| Systemic Candida |
4.1% |
| Toxic Epidermal Necrolysis |
4.1% |
| Atrial Fibrillation |
3.1% |
| Candida Infection |
3.1% |
| Vanishing Bile Duct Syndrome |
3.1% |
| Zygomycosis |
3.1% |
| Blood Bilirubin Increased |
2.1% |
| Bronchopulmonary Aspergillosis |
2.1% |
| Dilatation Intrahepatic Duct Acquired |
2.1% |
| Hallucination, Visual |
2.1% |
| Mediastinitis |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.0% |
| Drug Use For Unknown Indication |
20.0% |
| Infection |
7.1% |
| Prophylaxis |
6.8% |
| Acute Myeloid Leukaemia |
5.6% |
| Hiv Infection |
4.2% |
| Fungal Infection |
3.7% |
| Constipation |
3.6% |
| Sepsis |
3.0% |
| Antifungal Prophylaxis |
2.9% |
| Pyrexia |
2.7% |
| Aspergillosis |
2.5% |
| Hypertension |
2.5% |
| Immunosuppression |
2.3% |
| Sedation |
2.3% |
| Prophylaxis Against Graft Versus Host Disease |
2.2% |
| Febrile Neutropenia |
1.9% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Premedication |
1.9% |
| Aspergillus Infection |
1.8% |
|
| Thrombocytopenia |
8.9% |
| Septic Shock |
7.0% |
| Drug Ineffective |
6.6% |
| Respiratory Failure |
6.6% |
| Multi-organ Failure |
5.6% |
| Pyrexia |
5.6% |
| Sepsis |
5.2% |
| Weight Increased |
5.2% |
| White Blood Cell Count Decreased |
5.2% |
| Zygomycosis |
5.2% |
| Systemic Candida |
4.7% |
| Ureterostomy Site Discomfort |
4.7% |
| Pancytopenia |
4.2% |
| Renal Failure |
4.2% |
| Neutropenia |
3.8% |
| Staphylococcal Infection |
3.8% |
| Vomiting |
3.8% |
| Cardiac Failure |
3.3% |
| Death |
3.3% |
| Encephalopathy |
3.3% |
|
